Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
Randomized phase II clinical trial which aims to assess the impact on 3-month mortality and
safety of adding adalimumab to standard treatment (anti-tuberculosis drugs and
corticosteroids) in HIV patients with tuberculosis meningitis in 3 countries (Brazil,
Mozambique, and Zambia).